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Abstract
Introduction: The available data on the epidemiology of interstitial lung disease (ILD) from India is sparse. Hence, the present 
study was undertaken with the aim to analyse the demographic profile and clinical, radiological and pathological characteristics 
along with physiological parameters of various subgroups of ILD patients.
Material and methods: We retrospectively studied 289 patients diagnosed with ILD during the years 2001–2013 at one of the 
respiratory units of Vallabhbhai Patel Chest Institute.
Results: Mean age at presentation was 44.24 years; females comprised 54.68% of the patients. Prior to presentation at our 
centre, 14.84% patients had been treated with antituberculous therapy due to misdiagnosis of tuberculosis. In the pool of ILDs 
analysed, sarcoidosis (37.3%) was found to be the most common subgroup, followed by IPF (27.6%) and NSIP (25.6%). Cough 
(92.97%) was the most common presenting symptom; exertional dyspnoea was found in 79.2% of patients. Digital clubbing was 
commonest in IPF, found in 30% of patients. Significant desaturation on six-minute walk test was most frequenty seen (50%) in 
NSIP patients. The most common pattern on chest roentgenogram was reticular/reticulo-nodular pattern (80.2%) and on HRCT — 
interstitial fibrosis (49.9%). Mean of predicted total lung capacity (TLC) was 64.3%, the lowest being in the IPF group (58.88%). 
Mean of predicted DLCO was 50.56%, the lowest being in the IPF group (42.75%). The overall diagnostic yield of bronchoscopic 
biopsy was 83.04%, the highest yield being among sarcoidosis patients (96.29%). 
Conclusions: We found sarcoidosis, IPF and NSIP to be the most common ILDs in northern India. ILDs are still frequently mis-
diagnosed as TB, and increased awareness, education and diagnostic facilities are required to diagnose ILDs at an early stage. 
Key words: interstitial lung diseases, diffuse parenchymal lung diseases, idiopathic pulmonary fibrosis, high resolution computed 
tomography, sarcoidosis
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Streszczenie
Wstęp: Istnieje stosunkowo mało informacji dotyczących epidemiologii śródmiąższowych chorób płuc (ILD) w Indiach. Aktualna praca 
została podjęta w celu oceny danych demograficznych, kliniczno-patologicznych i fizjologicznych różnych typów chorób śródmiąższowych.
Materiał i metody: Badaniem retrospektywnym objęto 289 pacjentów, u których rozpoznano ILD w latach 2001–2013 w jednym 
z oddziałów Vallabhbhai Patel Chest Institute (Indie, Delhi).
Wyniki: Średni wiek chorych w chwili rozpoznania wynosił 44,4 roku, kobiety stanowiły 54,68% ogółu chorych. Z powodu myl-
nego rozpoznania gruźlicy 14,84% chorych było uprzednio leczonych przeciwprątkowo. Sarkoidozę rozpoznano u 37% chorych, 
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a IPF i NSIP odpowiednio w przypadku 27,6 i 25,6% chorych. Najczęściej zgłaszanymi objawami były kaszel (92,97%) i duszność 
wysiłkowa (79,2%) a palce pałeczkowate stwierdzono u 30% chorych na IPF. Znamienny spadek utlenowania krwi w 6-minuto-
wym teście chodu najczęściej obserwowano u chorych na NSIP (50%).
Zmiany guzkowo-siateczkowe w obrazie radiologicznym uwidoczniono u 80,2% chorych, a śródmiąższowe włóknienie w badaniu 
HRCT wykryto u 49,9% chorych.
Średnia wartość zdolności dyfuzyjnej płuc (DLCO) wynosiła 50,56% wartości należnej i była najbardziej upośledzona w grupie 
chorych na IPF (42,75%). Wartość diagnostyczna biopsji wykonanej podczas bronchoskopii wynosiła 83,04% i dotyczyła szcze-
gólnie chorych na sarkoidozę (96,29%)
Wnioski: Autorzy pracy stwierdzili, że w północnych Indiach najczęstszymi chorobami śródmiąższowymi są: sarkoidoza, IPF 
i NSIP. Śródmiąższowe choroby płuc są w Indiach często rozpoznawane błędnie jako gruźlica, dlatego konieczne jest szkolenie 
personelu i stworzenie ułatwień diagnostycznych, aby były one trafnie rozpoznane we wczesnym stadium. 
Słowa kluczowe: śródmiąższowe choroby płuc, rozlane miąższowe choroby płuc, samoistne włóknienie płuc, tomografia 
komputerowa o wysokiej rozdzielczości (HRCT), sarkoidoza
Pneumonol. Alergol. Pol. 2014; 82: 218–226 
Introduction
The term interstitial lung disease (ILD), or 
diffuse parenchymal lung disease (DPLD), encom-
passes a number of clinical disorders that involve 
the alveolar structures, pulmonary interstitium 
and small airways [1, 2]. Some of these diseases 
are benign and self-limiting; others are chronic, 
progressive, irreversible and even fatal. All ILDs, 
however, have certain common clinical, radiolo-
gical, pathological and physiological features that 
should be recognised. 
The available data on the frequency of occur-
rence of ILDs is sparse [3]. The incidence of ILDs 
is variable around the world. Literature shows the 
incidence of ILDs varying from 3.62 per 100,000 per-
son-years in southern Spain [4] to 31.5 per 100,000 
person-years in males and 26.1 per 100,000 person
-years in females in New Mexico, USA [5], a huge 
eightfold deviation in incidence across the globe.
In a developing country like India, with 
a high prevalence of tuberculosis (TB), ILDs are 
often initially misdiagnosed as TB. Data on ILDs 
has been limited to just a few dispersed studies 
[6–14]. The largest ILD series published from In-
dia comprised just 274 patients [13]. Also, most of 
the previous studies on ILD from India lacked any 
computed tomography (CT) evaluation. This re-
trospective study was, therefore, undertaken with 
the aim to study the spectrum of ILDs presenting 
to a tertiary care centre. The demographic profile 
and clinical, radiological and pathological charac-
teristics along with physiological parameters of 
these ILD patients were retrospectively analysed.
Material and methods
This study includes 289 patients diagnosed 
to have ILDs during the years 2001–2013 at one 
of the respiratory units at Vallabhbhai Patel Chest 
Institute, Delhi. The records of the patients were 
retrospectively reviewed for clinical presentation, 
and radiological and pathological findings along 
with their pulmonary function test at presen-
tation. The final diagnosis of ILD was based on 
histopathology wherever available, other cases 
were labelled as ILD on the basis of clinical and 
radiological parameters. The American Thoracic 
Society/European Respiratory Society Internatio-
nal Multidisciplinary Consensus Classification of 
Idiopathic Interstitial Pneumonias 2001 guideli-
nes were used in the diagnosis and classification 
of ILD [15]. The diagnosis of sarcoidosis was 
based on compatible clinical, radiological, labo-
ratory and/or histopathological features as per the 
joint statement of the American Thoracic Society, 
the European Respiratory Society and the World 
Association of Sarcoidosis and Other Granulo-
matous Disorders (ATS/ERS/WASOG) and also 
exclusion of any other causes of the same [16]. 
A detailed record of the medical history and 
examination at the time of initial presentation 
was analysed. Laboratory investigations such as 
haemogram, chest radiograph, electrocardiogram 
and sputum smear examination for acid-fast ba-
cilli (AFB), Mantoux test and pulmonary function 
test (PFT) were recorded. All serological inve-
stigations such as serum anti-nuclear antibody 
(ANA), serum calcium, serum angiotensin co-
nverting enzyme (ACE) levels, cytoplasmic anti-
neutrophil cytoplasmic antibodies (c-ANCA), pe-
rinuclear anti-neutrophil cytoplasmic antibodies 
(p-ANCA), anti topoisomerase I antibody (Scl-70) 
rheumatoid factor (RA), anti-cyclic citrullinated 
peptide antibodies (anti-CCP), anti double-stran-
ded DNA (anti-dsDNA), along with other relevant 
investigations such as 24-hour urinary calcium 
records, were obtained.
Pneumonologia i Alergologia Polska 2014, tom 82, nr 3, strony 218–226 
220 www.pneumonologia.viamedica.pl
Chest radiograph and high-resolution compu-
ted tomography (HRCT) findings were analysed. 
Fibre optic bronchoscopy (FOB), trans-bronchial 
lung biopsy (TBLB), endobronchial biopsy (EBB) 
and trans-bronchial needle aspiration (TBNA) 
had been performed in stable patients willing to 
undergo the procedure.
A six-minute walk test (6MWT) was performed 
in patients wherever indicated and desaturation of 
> 4% from baseline was considered as significant. 
In patients who were either not fit to undergo FOB 
or refused, the diagnosis was made on the basis of 
clinical, laboratory and radiological features. 
Results
The study included 289 patients diagnosed 
with interstitial lung disease on the basis of 
clinical radiological and pathological characte-
ristics. The overall mean age at presentation was 
44.24 years, 43.78 years in sarcoidosis and 53.83 
years in IPF. Of the 289 ILD cases there were 
158 (54.68%) females, and the majority (89.4%) 
were housewives. The overall mean duration 
of symptoms at diagnosis was 3.07 years: 2.35 
years in sarcoidosis and 2.23 years in IPF. The 
most frequent presenting symptom in the ILDs 
was cough, present in 268 (92.7%), followed by 
exertional dyspnoea in 229 (79.2%), arthralgia/ 
/arthritis in 32 (11.0%), fever in 30 (10.3%) and 
skin involvement in 11 (3.8%). Also, haemoptysis 
was present in 6 (2.07%) subjects. Dysphagia was 
observed in 5 (1.7%) cases, all belonging to the 
systemic sclerosis subgroup. The clinical profile 
disease-wise has been summarised in Table 1. 
Additionally, a disease-related summary of the ra-
diological and physiological findings of different 
ILDs in the study has been depicted in Table 2.
On examination, digital clubbing was noted 
in a total of 41 (14.1%) patients, with 30% in cases 
of IPF and 17.56% in cases of NSIP. Chest crepita-
tions were present in 273 (94.4%) of all patients. 
Prior history of anti-tuberculosis treatment due 
to misdiagnosis as tuberculosis was present in 43 
(14.8%) cases of ILD, with it being most common 
in sarcoidosis (22.22%). Significant desaturation 
on 6MWT was observed in 97 (33.56%) cases of 
ILD at presentation, with a frequency of 32.5% 
in IPF and 22.22% in sarcoidosis. All patients 
were sputum smear-negative for acid fast bacilli.
Chest roentgenogram revealed reticular/reti-
culo-nodular pattern in 232 (80.2%) and hilar-ade-
nopathy in 55 (19.03%) patients of ILD. The overall 
patterns documented on HRCT (n = 289) were in-
terstitial fibrosis (49.9%), honeycombing (37.71%), 
ground glass opacities (34.25%), intrathoracic 
lymphadenopathy (20.76%), traction bronchiec-
tasis (17.64%) and pleural fibrosis (5.8%). Honey-
combing was present in 4.62% cases of sarcoidosis, 
31.08% cases of NSIP and in all IPF cases. Pleural 
involvement was seen in 12.96% (14 subjects) of 
sarcoidosis subjects, in 2 subjects of rheumatoid 
arthritis-associated ILD and in 1 subject of SLE. No-
dular pattern was noted in 12.03% (13 subjects) of 
sarcoidosis subjects and in 57.14% (4 subjects) of 
hypersensitivity pneumonitis (HSP) subjects. Se-
rological evaluation in cases of sarcoidosis found 
that the mean level of serum ACE was 82.84 IU/L, 
serum calcium was 8.8 mg/dL and 24-hour urinary 
calcium levels were 308.23 mg/day. In cases of 
rheumatoid disease-associated ILDs, rheumatoid 
factor was positive in all 7 patients. Systemic sc-
lerosis was diagnosed on the basis of positive Anti 
Scl-70 antibody in all 5 cases. SLE was diagnosed 
in one patient with positive anti ds-DNA antibo-
dy. Skin biopsy showing granulomatous lesions 
consistent with sarcoidosis was reported in 3 pa-
tients (out of 108 sarcoidosis subjects), while the 
skin biopsies of 3 other patients had histological 
features suggestive of systemic sclerosis (out of 6 
systemic sclerosis subjects).
Spirometry was done in all cases, followed 
by static lung volume and diffusion capacity 
wherever possible. The mean TLC was 64.3% of 
predicted and DLCO was 50.56% of predicted 
with the DLCO/VA ratio being 92.9% of predicted. 
FOB was performed in all 289 patients, and biopsy 
reports (TBLB and/or EBB) were diagnostic in 240 
(83.04%) cases. 
Sarcoidosis
Sarcoidosis was diagnosed in 108 (37.37%) 
subjects in the present cohort. These comprised 
45 males and 63 females. The mean age at pre-
sentation was 43.78 years, with mean duration of 
symptoms being 2.35 years. The details of clinical 
symptoms, radiology, bronchoscopy findings and 
physiological parameters have been described in 
Table 1 and 2. 
Idiopathic pulmonary fibrosis 
Idiopathic pulmonary fibrosis was the se-
cond largest subgroup in the ILD subset. This 
subgroup included 80 (27.68%) patients and had 
a male-to-female ratio of 1:1. The average age at 
presentation was 53.83 years and mean duration 
of symptoms was 2.23 years. The detailed clinical, 
radiological, pathological and physiological pa-
rameters of this subgroup are depicted in Table 1 
and 2. 
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Table 1. Clinical profile of 289 interstitial lung disease patients
Total N (%) Sarcoido-
sis,  
N (%)
IPF  
N  
(%)
NSIP  
N  
(%)
HSP 
N
RA-
-ILD 
N
SS
N
SLE 
N
LIP 
N
DIP 
N
LCH 
N
PAP 
N
Number  
of subjects
289 108 
(37.37)
80 
(27.68)
74 (25.6) 7 6 6 1 2 3 1 1
Age (Years) 44.24 43.78 53.83 49.83 45.71 51.66 45.56 40 42 49.3 35 30
Male/Female 131 (45.32)/ 
/158 (54.68)
45 
(41.66)/ 
/63 (58.34)
40 
(50)/40 
(50)
34 
(45.94)/52 
(44.06)
5/2 5/1 1/5 0/1 0/2 1/2 0/1 0/1
Smoking 38 (13.14) 14 (12.96) 11 
(13.75)
10 (13.51) 0 1 0 0 0 2 0 0
Duration of 
symptoms (Yrs)
3.07 2.35 2.23 2.64 2.85 4.5 3.5 3 4.2 3.5 3 2
Cough 268 (92.73) 103 
(95.31)
71 
(88.75)
72 (97.29) 7 5 3 1 2 3 1 1
Dyspnoea 229 (79.23) 85 (78.70) 55 
(68.75)
70 (94.95) 5 4 3 1 2 3 1 1
Haemoptysis 6 (2.07) 2 (1.8) 1 (1.2) 3 (4.0) 0 0 0 0 0 0 0 0
Fever 30 (10.31) 12 (11.11) 10 
(12.5)
6 (8.1) 0 0 0 1 1 0 0 0
Joint  
Symptoms
32 (11.07) 12 (11.11) 7 (8.75) 5 (6.7) 0 7 0 1 0 0 0 0
ATT intake 43 (14.87) 24 (22.22) 9 
(11.25)
6 (8.1) 1 1 0 0 1 1 1 0
Clubbing 41 (14.18) 4 (3.7) 24 
(30.0)
13 (17.56) 0 0 0 0 0 0 0 0
Desaturation 
on 6MWT
97 (33.56) 24 (22.22) 26 
(32.5)
37 (50.0) 4 3 1 1 0 0 1 0
ATT — anti tubercular therapy, 6MWT — six minute walk test, IPF — idiopathic pulmonary fibrosis, NSIP — non-specific interstitial pneumonitis, HSP — hypersensiti-
vity pneumonitis, SLE — systemic lupus erythematosus, LIP — lymphoid interstitial pneumonitis, DIP — desquamative interstitial pneumonitis, LCH — Langerhan`s 
cell histiocytosis, PAP — pulmonary alveolar proteinosis, RA-ILD — rheumatoid arthritis associated interstitial lung disease; SS — systemic sclerosis
Nonspecific interstitial pneumonitis
This was the third largest subgroup in the 
studied cohort, comprising 74 (25.6%) patients; 
34 males and 52 females. The average age at pre-
sentation was 49.83 years, with mean duration of 
symptoms being 2.64 years. The detailed clinical 
history, radiological features, bronchoscopic eva-
luation and physiological parameters have been 
described in Table 1 and 2. 
The diagnosis of the remaining 27 patients 
included hypersensitivity pneumonitis (7), rheu-
matoid lung disease (6), systemic sclerosis (6), 
desquamative interstitial pneumonitis (3), lym-
phoid interstitial pneumonitis (2) and one case 
each of systemic lupus erythematosus, Lan-
gerhan’s cell histiocytosis (LCH) and pulmonary 
alveolar proteinosis. All of the findings of these 
patients have been described in detail in Table 1 
and 2. 
Discussion
The true burden of ILD in India is not clearly 
known due to under recognition, attributed to lack 
of awareness, paucity of diagnostic facilities as 
well as to the huge spectrum that this entity en-
compasses. Reports from western literature show 
an increase in the prevalence and incidence of ILD 
in recent decades [18]. However, data on clinical 
presentation and diagnosis of the spectrum of ILDs 
from India is limited. The results of previous Indian 
studies on ILDs are summarised in Table 3. The 
previous studies, depicted in Table 3, did not have 
uniform diagnostic case definition and classification 
criteria of ILDs and did not have computed tomo-
graphy evaluation in all studies. To the best of our 
knowledge, the present study is the first study of ILD 
epidemiology on an Indian population, with defined 
criteria [15, 16] of diagnosis and classification. 
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In our study, the mean age at presentation 
was greater than 40 years, with the exception of 
ILDs presenting at a younger age, such as LCH 
and PAM. This finding is similar to previous 
studies from India [6–14] as well as western 
literature [17, 18]. The present study observed 
increased prevalence in females (54.6%) as 
compared to male patients (45.3%). Similar ob-
servations have been reported in other Indian 
studies [7, 9, 12, 13] and also in a study from 
Greece. However, an increased prevalence in 
males has been documented in other studies 
[8, 10, 11, 14, 19]. This can be explained by the 
fact that the majority of our subject population 
consisted of patients with sarcoidosis and non-
specific interstitial pneumonia (NSIP), which 
are female preponderant diseases. In the pool 
of ILDs analysed, sarcoidosis (37.3%) was found 
to be the most common subgroup, followed by 
IPF (27.6%) and NSIP (25.6%). The results were 
similar to another Indian study [10] and stu-
dies from western literature [20, 21]. However, 
in a study on the occurrence of ILD in Poland 
based on patients hospitalised in the Regional 
Pulmonary Unit in Radom, IPF (27.5%) was the 
most common, followed by sarcoidosis (25%). 
The incidence of ILDs calculated for the adult 
population of this region was 5/100,000 [22]. 
Similarly, studies by Subhash et al. [12] and 
Udwadia et al. [13], from India, reported a higher 
prevalence of IPF in the study population. 
Another important observation is that almost 
15% of cases of ILDs had a history of anti-tuber-
cular treatment, and in the sarcoidosis subgroup 
this figure was 22%. This might be due to radio-
logical similarities between ILD and pulmonary 
tuberculosis and a lack of awareness and paucity 
of diagnostic facilities in remote areas. 
The current study included 108 (37.3%) cases 
of pulmonary sarcoidosis, 63 (58.3%) being fema-
les. The higher prevalence in females is coherent 
with findings in western literature [21]. The mean 
age at presentation was 43.78 years with the 
average duration of symptoms being 2.35 years; 
the majority were non-smokers (78.1%). This 
data is similar to other Indian studies [23, 24]. 
In accordance with the literature [21], clubbing 
(3.7%) was a rare finding in our study. Miliary 
pattern is an uncommon finding [25], although 
in the current study it was found in 12.03% of 
cases. 6MWT showed significant desaturation in 
24 (22.22%) cases. The plausible explanation of 
this could be the advanced stage of the disease at 
presentation. In bronchoscopic evaluation, only 
5 cases of sarcoidosis had visible mucosal nodules. 
The diagnostic yield of bronchoscopic biopsy was 
96.29%, similar to that observed in literature [26].
Idiopathic pulmonary fibrosis is a specific 
type of ILD, with characteristic radiological fe-
atures and histopathology. In the present study 
we had 80 (27.68%) cases of IPF, and it was the 
second most common subgroup in the pool of 
ILDs. In contrast, IPF was observed as the most 
common ILD in other Indian [11–13] and western 
studies [27, 28]. In the current study, mean age at 
presentation was 53.83 years, male to female ratio 
was 1:1 and only 13.75% of cases were smokers. 
The current study agrees with data from western 
literature [29–32] in terms of age at presentation 
with disease typically occurring in 6th–7th decade 
of life. The literature [31–34] shows more men 
being diagnosed with IPF than women and the 
majority being smokers. However, our study 
reported equal prevalence in male and female 
subjects and a lesser prevalence of smoking. In 
another Indian study by Subhash et al. [12], out 
of 33 cases of IPF, 16 were females and smoking 
was present in only 18% of all IPF cases. Another 
point that merits mention is that diagnostic crite-
ria vary across studies, leading to differences in 
epidemiological parameters of IPF. 
In our study, on 6MWT, 32.5% of cases 
showed significant desaturation (> 4%) at pre-
sentation. This finding has clinical implications 
as studies have advocated that desaturation (i.e. 
a decline in oxygen saturation to below 88%) during 
6MWT is a marker for increased risk of mortality 
[35]. In the current study, among the ILD subgro-
ups, subjects of IPF showed worse pulmonary 
function test results with mean TLC of 58.88% 
of predicted and DLCO 42.75% of predicted. 
A similar finding was observed in a study by Jindal 
et al. [7]; the cryptogenic fibrosing alveolitis (CFA) 
group (synonymous with idiopathic pulmonary 
fibrosis) [36] showing DLCO of 49.8 ± 15.9% of 
predicted. Studies [37, 38] have shown that DLCO 
is a reliable predictor of survival at baseline, and 
a threshold of approximately 40% of predicted 
value has been correlated with an increased risk 
of mortality.
In the present study, we had 74 (25.6%) cases 
with a diagnosis of NSIP based on clinical radio-
logical and pathological features, but we were 
unable to elucidate the cause. The mean age at 
presentation was 49.83 years, 52 were females and 
only 13.5% were smokers. The review of literature 
shows NSIP has a mean age of 52 years and is 
more common in females and never smokers [39].
Patients diagnosed with connective tissue 
disease (CTD)-ILD may have a classifiable CTD 
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at the time of diagnosis of ILD; however, in up 
to 25% of cases clinical and serological findings 
suggest, but are not entirely diagnostic of, a clas-
sifiable CTD [40]. Of 13 cases diagnosed as CTD
-associated interstitial lung disease (CTD-ILD), 
lung involvement at presentation was observed 
in 6 cases each of rheumatoid arthritis (RA) and 
scleroderma; only 1 case of SLE was noted. The 
prevalence of RA-ILD varies from 5–58% [40] and 
ILD in systemic sclerosis is observed in 40–80% 
of cases [41, 42]. The prevalence of CTD–ILD in 
India has been reported as ranging from 5.6% to 
50.8% in various studies [7, 10].
Hypersensitivity pneumonitis (HSP) was 
diagnosed in 7 (2.03%) cases; all were asso-
ciated with pigeon exposure, with duration of 
exposure ranging from 3–10 years. All 7 cases 
had histopathological confirmation of features 
consistent with diagnosis of HSP. In a previous 
study from India, Udwadia et al. [13] reported 
HSP in 15 (6%) from a total of 273 cases. Other 
ILDs diagnosed as per clinico-radio-pathological 
criteria in the current study were desquamative 
interstitial pneumonia (DIP) 3 cases, lymphocytic 
interstitial pneumonia (LIP) 2 cases and one case 
each of pulmonary Langerhans cell histiocytosis 
and pulmonary alveolar proteinosis. 
Conclusions
The current study describes the spectrum of 
ILDs prevalent in northern India. Diagnosis of 
ILDs at an early stage is paramount to prevent/ 
/delay progression to irreversible damage to the 
lungs, especially in treatment-responsive ILDs 
like sarcoidosis. Hence, in a developing country 
like India, with high prevalence of pulmonary 
tuberculosis, education and awareness of general 
practitioners and physicians about ILDs deserves 
special attention.
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